{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:15:31Z","timestamp":1763565331169,"version":"3.45.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Translumina GmbH"},{"name":"Deutsches Herzzentrum M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We aimed to evaluate a novel polymer-free hybrid drug eluting stent\u00a0(DES) relative to benchmark devices and specific controls addressing singular components of the test device in a juvenile pig model of coronary stenting. 80 stents were implanted in 28 juvenile pigs and evaluated at 28 and 90\u00a0days using quantitative coronary angiography and histopathology (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910 per group). Scanning electron microscopy was used at 14\u00a0days to assess early re-endothelialization (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093 per group). The test device featured a cobalt-chromium (CoCr) backbone with a polymer-free probucol matrix releasing everolimus. The polymer-free test stent showed improved strut coverage at 28\u00a0days compared to the polymer-coated control, with significantly lower neointimal growth at 90\u00a0days and near complete endothelialization at 14\u00a0days. This preclinical study supports the favorable vascular healing profile of a polymer-free hybrid DES, warranting further clinical investigation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Preclinical assessment of a novel polymer-free DES. The polymer-free coating strategy demonstrated a favorable healing profile in both short- and mid-term evaluation compared to polymer-based benchmark devices<\/jats:p>","DOI":"10.1007\/s12265-025-10680-5","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:28:34Z","timestamp":1755264514000},"page":"1383-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Assessment of a Novel Polymer-Free Hybrid Drug Eluting Stent"],"prefix":"10.1007","volume":"18","author":[{"given":"L\u00e9a","family":"Wild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Beele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Seguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emina","family":"Sabic-Halilcevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace R.","family":"Klosterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-8310","authenticated-orcid":false,"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"5","key":"10680_CR1","first-page":"567","volume":"57","author":"RA Byrne","year":"2009","unstructured":"Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57(5):567\u201384.","journal-title":"Minerva Cardioangiol"},{"issue":"9","key":"10680_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2165\/11316500-000000000-00000","volume":"32","author":"RA Byrne","year":"2009","unstructured":"Byrne RA, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. 2009;32(9):749\u201370.","journal-title":"Drug Saf"},{"issue":"1","key":"10680_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193\u2013202.","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"10680_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","volume":"36","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147\u201359.","journal-title":"Eur Heart J"},{"issue":"9","key":"10680_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.4244\/EIJY14M10_08","volume":"11","author":"T Koppara","year":"2016","unstructured":"Koppara T, et al. Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting. EuroIntervention. 2016;11(9):1020\u20136.","journal-title":"EuroIntervention"},{"issue":"2","key":"10680_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jacc.2020.05.026","volume":"76","author":"S Kufner","year":"2020","unstructured":"Kufner S, et al. 10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents. J Am Coll Cardiol. 2020;76(2):146\u201358.","journal-title":"J Am Coll Cardiol"},{"key":"10680_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ahj.2021.02.009","volume":"235","author":"T Pilgrim","year":"2021","unstructured":"Pilgrim T, et al. Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. Am Heart J. 2021;235:140\u20138.","journal-title":"Am Heart J"},{"issue":"1","key":"10680_CR8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41598-022-26654-5","volume":"13","author":"J Yin","year":"2023","unstructured":"Yin J, et al. Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta-analysis. Sci Rep. 2023;13(1):1715.","journal-title":"Sci Rep"},{"issue":"2","key":"10680_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0735-1097(92)90476-4","volume":"19","author":"RS Schwartz","year":"1992","unstructured":"Schwartz RS, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267\u201374.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10680_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","volume":"129","author":"F Otsuka","year":"2014","unstructured":"Otsuka F, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211\u201323.","journal-title":"Circulation"},{"issue":"5","key":"10680_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","volume":"52","author":"M Joner","year":"2008","unstructured":"Joner M, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10680_CR12","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","volume":"103","author":"A Kastrati","year":"2001","unstructured":"Kastrati A, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103(23):2816\u201321.","journal-title":"Circulation"},{"issue":"6","key":"10680_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4244\/EIJV8I6A115","volume":"8","author":"K Steigerwald","year":"2012","unstructured":"Steigerwald K, et al. Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. EuroIntervention. 2012;8(6):752\u20139.","journal-title":"EuroIntervention"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10680-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:12:14Z","timestamp":1763565134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10680-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10680"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10680-5","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"type":"print","value":"1937-5387"},{"type":"electronic","value":"1937-5395"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No human studies were carried out by the authors for this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the appropriate institutional committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"L.W. received honoraria for a speaking engagement from Translumina GmbH. M.S. reports honoraria from Amgen, Biotronik, Kowa, NIPRO and Novartis, not related to the current work. A.K. reports participation on the data safety monitoring\/advisory board TARGET IV funded by CRF New York, as well as issued patent PCT\/EP2021\/053116 and an applied patent regarding DES technology, not related to the current work. M.J. received personal fees from Abbot, Alchimedics S.A.S, Astra Zeneca, Biotronik, Medtronic, Recor, TriCares and Veryan, as well as grants and personal fees from Boston Scientific and Edwards outside the submitted work. All other authors have nothing to disclose\u00a0and have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}